Cresset Asset Management, LLC Bluebird Bio, Inc. Transaction History

Cresset Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.07 - $10.6 $103,866 - $270,512	-25,520 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$8.96 - $16.31 $75,774 - $137,933	8,457 Added 49.56%	25,520 $255,000
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $78,927 - $147,462	7,022 Added 69.93%	17,063 $326,000
Q2 2021 Aug 10, 2021	BUY	$18.04 - $22.09 $181,139 - $221,805	10,041 New	10,041 $322,000
Q2 2019 Aug 12, 2019	SELL	$75.84 - $105.21 $379 - $526	-5 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $322 - $520	5 New	5 $1,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cresset Asset Management, LLC with notifications on news.